Investigate Safety, Tolerability, PK, PD and Efficacy of RO7034067 in Infants With Type1 Spinal Muscular Atrophy (FIREFISH)

  • Spinal Muscular Atrophy (SMA)
Trial Status:

Active, not recruiting

This trial runs in
Countries
  • Belgium
  • Brazil
  • China
  • Croatia
  • France
  • Italy
  • Japan
  • Poland
  • Russia
  • Serbia
  • Spain
  • Switzerland
  • Turkey
  • Ukraine
  • United States
Trial Identifier:

NCT02913482 2016-000778-40 BP39056

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      Open-label, multi-center clinical study is to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and efficacy of Risdiplam (RO7034067) in infants with Type 1 spinal muscular atrophy (SMA). The study consists of two parts, an exploratory dose finding part (Part 1) and a confirmatory part (Part 2) which will investigate Risdiplam (RO7034067) for 24-months at the dose selected in Part 1.

      Hoffmann-La Roche Sponsor
      Phase 2/Phase 3 Phase
      NCT02913482 , BP39056 , 2016-000778-40 Trial Identifier
      RO7034067 Treatments
      Muscular Atrophy, Spinal Condition
      Official Title

      A Two Part Seamless, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Infants With Type 1 Spinal Muscular Atrophy

      Eligibility Criteria

      All Gender
      ≥ 1 Month & ≤ 7 Months Age
      No Healthy Volunteers
      Inclusion Criteria
      • Clinical history, signs or symptoms attributable to Type 1 SMA with onset after 28 days but prior to the age of 3 months
      • Gestational age of 37 to 42 weeks
      • Confirmed diagnosis of 5q-autosomal recessive SMA
      • Participants has two survival motor neuron 2 (SMN2) gene copies, as confirmed by central testing
      • Body weight greater than or equal to (>=) third percentile for age, using appropriate country-specific guidelines
      • Receiving adequate nutrition and hydration (with or without gastrostomy) at the time of screening, in the opinion of the Investigator
      • Adequately recovered from any acute illness at the time of screening and considered well-enough to participate in the opinion of the Investigator
      Exclusion Criteria
      • Concomitant or previous participation in any investigational drug or device study within 90 days prior to screening or 5 half-lives, whichever is longer
      • Concomitant or previous administration of SMN2-targeting antisense oligonucleotide, SMN2 splicing modifier or gene therapy study
      • Any history of cell therapy
      • Hospitalization for pulmonary event within the last 2 months, or planned at the time of screening
      • Presence of clinically relevant electrocardiogram (ECG) abnormalities before study drug administration
      • Unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular system diseases
      • Participants requiring invasive ventilation or tracheostomy
      • Participants requiring awake non-invasive ventilation or with awake hypoxemia (arterial oxygen saturation less than [<] 95 percent [%]) with or without ventilator support
      • Participants with a history of respiratory failure or severe pneumonia, and have not fully recovered their pulmonary function at the time of screening
      • Multiple or fixed contractures and/or hip subluxation or dislocation at birth
      • Presence of non-SMA related concurrent syndromes or diseases
      • Any major illness within one month before the screening examination or any febrile illness within one week prior to screening and up to first dose administration
      • Any inhibitor of cytochrome P450 (CYP) 3A4 and/or any Organic Cation Transporter 2 (OCT-2) and multidrug and toxin extrusion (MATE) substrates taken within 2 weeks and/or any inducer of CYP3A4 taken within 4 weeks (or within 5-times the elimination half-life, whichever is longer) prior to dosing or participants (and the mother, if breastfeeding the infant) taking any nutrients known to modulate CYP3A activity and any known flavin containing monooxygenase (FMO) 1 or FMO3 inhibitors or substrates
      • Prior use (at any time in the participants lives) and/or anticipated need for quinolones (chloroquine and hydroxychloroquine), thioridazine, vigabatrin, retigabine, or any other drug known to cause retinal toxicity during the study. Infants exposed to chloroquine, hydroxycholoroquine, thioridazine, vigabatrin, retigabine or drugs with known retinal toxicity given to mothers during pregnancy (and lactation) should not be enrolled.
      • Recent history (less than 6 months) of ophthalmic disease that would interfere with the conduct of the study as assessed by an ophthalmologist
      • Therapeutic use, defined as use for 8 weeks or longer, of the following medications within 90 days prior to enrollment: riluzole, valproic acid, hydroxyurea, sodium phenylbutyrate, butyrate derivatives, creatine, carnitine, growth hormone, anabolic steroids, probenecid, agents anticipated to increase or decrease muscle strength, agents with known or presumed histone deacetylase (HDAC) inhibitory effect, medications known to or suspected of causing retinal toxicity (deferoxamine, topiramate, latanoprost, niacin, rosiglitazone, tamoxifen, canthaxanthine, sildenafil, and interferon) and medications with known phototoxicity liabilities (e.g., oral retinoids including over-the-counter [OTC] formulations, amiodarone, phenothiazines and use of minocycline)

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now